News
GCTK
0.2820
-1.47%
-0.0042
GlucoTrack Inc trading halted, news pending
TipRanks · 23h ago
GlucoTrack Executes Reverse Stock Split to Restructure Shares
TipRanks · 1d ago
GlucoTrack subsidiary initiates clinical trial manufacturing for LT-100
TipRanks · 4d ago
Glucotrack's Lōkahi Therapeutic Subsidiary Initiates Good Manufacturing Practice Production Campaign For LT-100
Benzinga · 4d ago
Weekly Report: what happened at GCTK last week (0817-0821)?
Weekly Report · 5d ago
Lokahi expands ai2 Future Labs asset origination netowrk
TipRanks · 08/21 12:05
GlucoTrack Shareholders Approve Key Governance and Capital Actions
TipRanks · 08/19 13:27
GlucoTrack achieves key compliance milestone
TipRanks · 08/17 12:11
Glucotrack Announces That Nasdaq Hearings Panel Has Granted The Company's Request For Continued Listing, Subject To Conditions
Benzinga · 08/17 12:06
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 08/17 12:06
Weekly Report: what happened at GCTK last week (0810-0814)?
Weekly Report · 08/17 09:33
GlucoTrack Amends Equity Financing and Issues Commitment Shares
TipRanks · 08/10 22:17
Weekly Report: what happened at GCTK last week (0803-0807)?
Weekly Report · 08/10 09:31
GlucoTrack Secures New Financing to Support Growth
TipRanks · 08/05 22:24
GlucoTrack announces $5.5M financing
TipRanks · 08/05 14:14
Glucotrack raises $5.5M in equity and convertible debt financing
Seeking Alpha · 08/05 13:05
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 08/04 21:06
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in July 2026
Seeking Alpha · 08/03 13:45
Weekly Report: what happened at GCTK last week (0727-0731)?
Weekly Report · 08/03 09:31
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 07/31 17:05
More
Webull provides a variety of real-time GCTK stock news. You can receive the latest news about Glucotrack through multiple platforms. This information may help you make smarter investment decisions.
About GCTK
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.